SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Gold/Mining/Energy : Nuvo Research Inc
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Cal Gary who wrote (4098)4/13/2000 7:19:00 PM
From: Mark Bartlett  Read Replies (1) of 14101
 
Cal,

I think as far as QLT is concerned, the FDA approval was already pretty much built into the price -- so I am not sure that DMX, upon approval, would act the same way. There is absolutely NOTHING else available for the condition that QLT was treating, so the FDA would have had to have very compelling reason for NOT approving that particular med.

In DMX's case there are other meds on the market to treat the condition. They may not have the same potential benefits that Pennsaid has, but it is not like there is NOTHING else. This is not to say that there are not very compelling reasons to approve Pennsaid (IMO there are, or I would not be here) but they sense of urgency (in terms of time lines) is not as strong -- makes sense.

Do not expect the Nasdaq listing until the later part of this year - my guess would be after September to December. In light of the present market sentiment, that may well prove to be a plus.

MB
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News